Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | CCR2 | P41597 | 16/20 | 0.51 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL306049 | 0.91 | TSHR (0.51) | CYP2C9CCR2TSHR | |
| SCHEMBL12593798 | 0.83 | CYP2C9 (0.49) | CYP2C9CCR2PGAM1TSHR | |
| SCHEMBL3090250 | 0.83 | CCR2 (0.59) | CCR2PGAM1 | |
| SCHEMBL21084894 | 0.82 | CCR2 (0.49) | CYP2C9CCR2PGAM1TSHR | |
| SCHEMBL21085231 | 0.80 | CYP2C9 (0.46) | CYP2C9CCR2TSHR | |
| SCHEMBL306044 | 0.80 | CCR2 (0.64) | CYP2C9CCR2TSHR | |
| SCHEMBL18714270 | 0.80 | CCR2 (0.63) | CYP2C9CCR2TSHR | |
| SCHEMBL306510 | 0.80 | CYP3A4 (0.57) | CYP2C9CCR2PGAM1TSHR | |
| SCHEMBL126997 | 0.79 | CYP2C9 (0.66) | CYP2C9CCR2TSHR | |
| SCHEMBL305754 | 0.79 | CYP2C9 (0.66) | CYP2C9CCR2PGAM1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | CYP2C9 192/4885CCR2 1/4885PGAM1 4335/4885 |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | CYP2C9 192/4885CCR2 1/4885PGAM1 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.